Premium
HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications
Author(s) -
Kaul Daniel R.,
Cinti Sandro K.,
Carver Peggy L.,
Kazanjian Powel H.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.4.281.30937
Subject(s) - saquinavir , amprenavir , protease , adverse effect , medicine , human immunodeficiency virus (hiv) , pharmacology , protease inhibitor (pharmacology) , virology , biology , antiretroviral therapy , hiv 1 protease , enzyme , viral load , biochemistry
Protease inhibitors (PIs) effectively inhibit replication of the human immunodeficiency virus (HIV), and reduce mortality and prolong survival in patients with HIV infection. Newer PIs saquinavir (soft gelatin capsule) and amprenavir, as well as other PIs, may be effective when administered twice/day. Adverse reactions may occur, as well as metabolic complications and interactions between PIs and other drugs, including other PIs. The strategy of combining PIs is based on specific pharmacologic interactions among the agents.